Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 4/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | KLK7 | P49862 | 1/20 | 0.62 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.61 |
| ▸ | GFER | P55789 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4724457 | 1.00 | PREP (0.67) | PREPNPSR1FKBP1AALDH1A1TSHR | |
| SCHEMBL5525089 | 1.00 | PREP (0.67) | PREPNPSR1FKBP1AALDH1A1TSHR | |
| SCHEMBL630096 | 0.96 | FKBP1A (0.71) | PREPNPSR1FKBP1AALDH1A1TSHR | |
| SCHEMBL3578099 | 0.96 | FKBP1A (0.71) | PREPNPSR1FKBP1AALDH1A1TSHR | |
| SCHEMBL17469372 | 0.95 | PREP (0.71) | PREPNPSR1FKBP1AALDH1A1TSHR | |
| SCHEMBL19258206 | 0.95 | PREP (0.71) | PREPNPSR1FKBP1AALDH1A1TSHR | |
| SCHEMBL17469393 | 0.95 | PREP (0.71) | PREPNPSR1FKBP1AALDH1A1TSHR | |
| SCHEMBL17469366 | 0.95 | PREP (0.71) | PREPNPSR1FKBP1AALDH1A1TSHR | |
| SCHEMBL2769697 | 0.92 | PREP (0.60) | PREPNPSR1FKBP1AALDH1A1TSHR | |
| SCHEMBL1056362 | 0.92 | PREP (0.60) | PREPNPSR1FKBP1AALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12599672-B2 | KRAS proteolysis targeting chimeras | PAQ Therapeutics Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20250144225-A1 | KRAS Proteolysis Targeting Chimeras | PAQ Therapeutics Inc. (US) | 2025-05-08 | — | — | US | disclosed |
| WO-2025076044-A1 | KRAS PROTEOLYSIS TARGETING CHIMERAS | PAQ Therapeutics Inc. (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20240140957-A1 | BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF | BEONE MEDICINES I GMBH (CH) | 2024-05-02 | — | — | US | disclosed |
| US-11873365-B2 | Catatlyst components for the polymerization of olefins | BASELL POLIOLEFINE ITALIA S.R.L. (IT) | 2024-01-16 | — | — | US | disclosed |
| US-11873365-B2 | Catatlyst components for the polymerization of olefins | BASELL POLIOLEFINE ITALIA S.R.L. (IT) | 2024-01-16 | — | — | US | disclosed |
| CN-117180290-A | Arginase inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2023-12-08 | — | — | CN | disclosed |
| WO-2023215906-A1 | KRAS G12D PROTEOLYSIS TARGETING CHIMERAS | HANGZHOU JIJING PHARMACEUTICALTECHNOLOGY LIMITED (CN) | 2023-11-09 | — | — | WO | disclosed |
| EP-3334710-B1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | ALZHEON INC (US) | 2023-10-04 | — | — | EP | disclosed |
| WO-2023178299-A1 | PRODRUGS OF GANAXOLONE | MARINUS PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-1998023644-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1998-06-04 | — | — | WO | disclosed |
| US-5733912-A | NERVOUS SYSTEM DISORDERS IN NERVE CELLS | ABBOTT LABORATORIES (US) | 1998-03-31 | — | — | US | disclosed |
| WO-1997046578-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1997-12-11 | — | — | WO | disclosed |
| EP-0663912-A1 | HETEROCYCLIC ETHER COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION | ABBOTT LABORATORIES (US) | 1995-07-26 | — | — | EP | disclosed |
| US-5409946-A | Antiepileptic agent | ABBOTT LABORATORIES (US) | 1995-04-25 | — | — | US | disclosed |
| EP-0663912-A4 | HETEROCYCLIC ETHER COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION. | ABBOTT LAB (US) | 1995-02-17 | — | — | EP | disclosed |
| WO-1994008992-A1 | HETEROCYCLIC ETHER COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION | ABBOTT LABORATORIES (US) | 1994-04-28 | — | — | WO | disclosed |
| EP-0588917-A4 | — | — | 1994-04-13 | — | — | EP | disclosed |
| EP-0588917-A1 | ISOXAZOLE AND ISOTHIAZOLE COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION | ABBOTT LABORATORIES (US) | 1994-03-30 | — | — | EP | disclosed |
| WO-1992021339-A1 | ISOXAZOLE AND ISOTHIAZOLE COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION | ABBOTT LABORATORIES (US) | 1992-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12599672-B2 | KRAS proteolysis targeting chimeras | KRAS, HRAS, NRAS | PREP 983/4885NPSR1 4342/4885FKBP1A 3135/4885 |
| US-20250144225-A1 | KRAS Proteolysis Targeting Chimeras | KRAS, HRAS, NRAS | PREP 133/4885NPSR1 3911/4885FKBP1A 2851/4885 |
| US-20240140957-A1 | BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF | KRAS, NRAS, G3BP1 | PREP 827/4885NPSR1 3741/4885FKBP1A 3093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.